Acadia Pharmaceuticals (ACAD) Tax Provisions (2017 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Tax Provisions of $300000.0 for Q1 2026, down 96.59% year-over-year from $8.8 million in Q1 2025, and up 101.5% quarter-over-quarter from -$20.0 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Tax Provisions (2017 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Tax Provisions history runs 10 years deep, the most recent figure standing at $300000.0 for Q1 2026.
- In Q1 2026, Tax Provisions fell 96.59% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at -$33.4 million (down 424.3% YoY), while the FY2025 annual figure was -$24.8 million, down 516.43% from the prior year.
- Tax Provisions for Q1 2026 stood at $300000.0, up from -$20.0 million in the prior quarter.
- The five-year high for Tax Provisions was $13.5 million in Q2 2025, with the low at -$27.2 million in Q3 2025.
- The 5-year median for Tax Provisions is $768000.0 (2022), against an average of -$346882.4.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions soared 2209.52% in 2022, then slumped 856.25% in 2023.
- Acadia Pharmaceuticals' Tax Provisions stood at $800000.0 in 2022, then plunged by 856.25% to -$6.0 million in 2023, then plunged by 37.85% to -$8.3 million in 2024, then slumped by 140.04% to -$20.0 million in 2025, then surged by 101.5% to $300000.0 in 2026.
- Business Quant data shows ACAD's Tax Provisions at $300000.0 in Q1 2026, -$20.0 million in Q4 2025, and -$27.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 15.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.00 Mn |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | -20.02 Mn |
| Sep 30, 2025 | -27.18 Mn |
| Jun 30, 2025 | 13.55 Mn |
| Mar 31, 2025 | 8.79 Mn |
| Dec 31, 2024 | -8.34 Mn |
| Sep 30, 2024 | 6.04 Mn |
| Jun 30, 2024 | 3.79 Mn |
| Mar 31, 2024 | 4.40 Mn |
| Dec 31, 2023 | -6.05 Mn |
| Sep 30, 2023 | 13.00 Mn |
| Jun 30, 2023 | 5.23 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | 800,000.00 |
| Sep 30, 2022 | 768,000.00 |
| Jun 30, 2022 | 443,000.00 |
| Mar 31, 2022 | 485,000.00 |
| Dec 31, 2021 | 3.72 Mn |
| Sep 30, 2021 | -332,000.00 |